Showing results (111-120 of 125) with videos related to

Sort By:
Pageof 13
Deutsche Medizinische Wochenschrift (1946)|October 8, 1993
[Color-coded duplex ultrasonography in the diagnosis of renal artery stenosis]T Karasch, A L Strauss, B Grün, et al.
Quality & Safety in Health Care|April 30, 2010
Patient-specific electronic decision support reduces prescription of excessive dosesH M Seidling, S P W Schmitt, T Bruckner, et al.
The Pharmacogenomics Journal|August 25, 2011
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort studyG Yimer, W Amogne, A Habtewold, et al.
Journal of Affective Disorders|December 19, 2018
Association of generalized anxiety symptoms and panic with health care costs in older age-Results from the ESTHER cohort studyJ K Hohls, B Wild, D Heider, et al.
BMC Geriatrics|July 17, 2021
Assessing the perspective of well-being of older patients with multiple morbidities by using the LAVA tool - a person-centered approachB Wild, V S Wurmbach, F Böhlen, et al.
Mund-, Kiefer- Und Gesichtschirurgie : MKG|April 3, 2007
[The importance of dental-based treatment shown on the case report of a pontine abscess caused by Streptococcus viridans]U D A Müller-Richter, S Bele, J C Roldán, et al.
Clinical Pharmacology and Therapeutics|March 3, 2007
CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavirF Josephson, A Allqvist, M Janabi, et al.
Clinical Pharmacology and Therapeutics|October 1, 2010
Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patientsE Ngaimisi, S Mugusi, O M Minzi, et al.
Clinical Pharmacology and Therapeutics|August 5, 2011
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosisE Ngaimisi, S Mugusi, O Minzi, et al.
Chemotherapy|November 24, 1999
Isoniazid plus sulphadoxine-pyrimethamine can reduce morbidity of HIV-positive patients treated for tuberculosis in Africa: a controlled clinical trialL Haller, R Sossouhounto, I M Coulibaly, et al.
Pageof 13